February 15, 2017

BioCanRX makes a major investment in Canadian biotherapeutics research

 

CAT-T

Biotherapeutics, a relatively new class of treatments, have shown great promise and are generating a lot of excitement in the cancer research community. These treatments harness the power of oncolytic viruses, cell therapies and antibodies to kill cancer. BioCanRX, Canada’s biotherapeutics research network, has announced $11 million in funding for 16 projects that will enable scientists across the country to bring their innovations to patients sooner.

Continue reading – BioCanRX makes a major investment in Canadian biotherapeutics research

November 2, 2016

FACIT start-up Turnstone Biologics closes USD $41M financing

OrbiMed, Versant-led round continues commercialization success for Turnstone’s cancer therapies

John Bell and contributorsTORONTO, Nov. 2, 2016 /CNW/ – Turnstone Biologics Inc. (“Turnstone”), an Ontario-based developer of novel oncolytic viral immunotherapies, announced the closing of a USD $41.4 million Series B financing led by OrbiMed Advisors LLC (“OrbiMed”) and Versant Ventures (“Versant”), which led Turnstone’s Series A round in October 2015. New investor F-Prime Capital Partners (“F-Prime”) and existing founding investor FACIT also participated. Proceeds from the financing will support an ongoing Phase I/II clinical trial in patients with advanced or metastatic solid tumours as well as accelerate and expand Turnstone’s pipeline, funding the development of three additional programs into the clinic. In connection with the financing Orbimed’s Rishi Gupta, JD and F-Prime’s Ben Auspitz will join Turnstone’s board of directors alongside Versant’s Brad Bolzon, PhD and Jerel Davis, PhD as well as FACIT’s Jeff Courtney.

Continue reading – FACIT start-up Turnstone Biologics closes USD $41M financing